Advertisement

La chimiothérapie intrapéritonéale a-t-elle une place en première ligne?

  • L. Gladieff
Part of the Abord clinique book series (ONCOLPRAT)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Alberts D, Markman M, Armstrong DK et al. (2002) Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come! J Clin Oncol 19: 3944–6Google Scholar
  2. 2.
    Dedrick RL, Myers CE, Bungay PM et al. (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62: 1–11PubMedGoogle Scholar
  3. 3.
    Markman M (1993) Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavity. Critical Review in Oncol Hematol 14: 15–28Google Scholar
  4. 4.
    Myers C (1984) The use of intraperitoneal chemotherapy in the treatment of ovarian cancer. Semin Oncol 11: 275–84PubMedGoogle Scholar
  5. 5.
    Dedrick R, Flessner M (1997) Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst 89: 480–7CrossRefPubMedGoogle Scholar
  6. 6.
    Pujade-Lauraine E, Boiron C (1996) Chimiothérapie intrapéritonéale. In: Arnette Blackwell (ed) Cancer de l’Ovaire. J. Dauplat et JP. Guastalla, Paris, p 479Google Scholar
  7. 7.
    Makhija S, Leitao M, Sabbatini P et al. (2001) Complications associated with intraperitoneal chemotherapy catheters. Gynecol Oncol 81: 77–81CrossRefPubMedGoogle Scholar
  8. 8.
    Zylberberg B, Dormont D, Ravina JH et al. (1991) Carcinomes ovariens: chimiothérapie intrapéritonéale à l’aiguille. Presse Med 20: 1320–6PubMedGoogle Scholar
  9. 9.
    Gladieff L, Chatelut E, Gaspard MH et al. (1999) Intraperitoneal high dose chemotherapy as consolidation treatment for advanced ovarian carcinoma: a pilot study. Bull Cancer 86: 673–7PubMedGoogle Scholar
  10. 10.
    Los G Mutsaers HA Van der Vijgh et al. 1989 Direct diffusion of cis-diamminedichloroplatinum II in intraperitoneal rat tumors after intraperitoneal chemotherapy a comparison with systemic chemotherapy. Cancer Res 49 3380–4PubMedGoogle Scholar
  11. 11.
    Canal P, Chatelut E, de Forni M et al. (1989) Comparaison de la pharmacocinétique du cisplatine administré par voie intrapéritonéale á deux posologies: 100 et 200 mg/m2. Bull Cancer 76: 879–82PubMedGoogle Scholar
  12. 12.
    Howell S, Pfeifle C, Wung W et al. (1982) Intraperitoneal cisplatin with systemic thiosulfate protection. Annals Intern Med 97: 845–51Google Scholar
  13. 13.
    Los G, Verdegaal E, Mutsaers HA et al. (1991) Penetration of carboplatin and cisplatin into rat peritoneal tumors nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol 28: 159–66CrossRefPubMedGoogle Scholar
  14. 14.
    Markman M, Rowinsky E, Hakes T et al. (1991) Phase I trial of intraperitoneal Taxol: a Gynaecologic Oncology Group study. J Clin Oncol 10: 1485–91Google Scholar
  15. 15.
    Prudence F, Rowinsky E, Schneider J et al. (1995) Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynaecologic Oncology Group pilot study. J Clin Oncol 13: 2961–7Google Scholar
  16. 16.
    Markman M, Brady M, Spirtos N et al. (1998) Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynaecologic Oncology Group study. J Clin Oncol 16: 2620–4PubMedGoogle Scholar
  17. 17.
    Fujiwara K, Sakuragi N, Suzuki S et al. (2003) First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up. Gynecol Oncol 90: 637–43CrossRefPubMedGoogle Scholar
  18. 18.
    Howell SB, Kirmani S, Lucas WE et al. (1990) A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer. J Clin Oncol 8: 137–45PubMedGoogle Scholar
  19. 19.
    Hofstra LS, Bos AME, de Vries EGE et al. (2002) Kinetic modeling and efficacy of intraperitoneal paclitaxel combined with intravenous cyclophosphamide and carboplatin as first line treatment in ovarian cancer. Gynecol Oncol 85: 517–23CrossRefPubMedGoogle Scholar
  20. 20.
    Rothenberg M, Liu PY, Braly P et al. (2003) Combined intra peritoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial. J Clin Oncol 21: 1313–9PubMedGoogle Scholar
  21. 21.
    Zylberberg B, Dormont D, Madelenat P et al. (2004) First line intraperitoneal cisplatinpaclitaxel and intravenous ifosfamide in stage IIIc ovarian epithelial cancer Eur J Gynaec Oncol XXV: 327–32Google Scholar
  22. 22.
    Bristow RE, Tomacruz RS, Armstrong DK et al. (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20: 1248–59CrossRefPubMedGoogle Scholar
  23. 23.
    Alberts D, Liu PY, Hannigan E et al. (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335: 1950–5CrossRefPubMedGoogle Scholar
  24. 24.
    Markman M, Bundy B, Alberts D et al. (2001) Phase III standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the gynaecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19: 1001–7PubMedGoogle Scholar
  25. 25.
    Armstrong DK, Bundy BN, Baergen R et al. (2002) Randomized phase III study of intravenous paclitaxel and cisplatin versus intravenous paclitaxel, intraperitoneal cisplatin and intraperitoneal paclitaxel in optimal stage III epithelial ovarian cancer: a Gynecologic Oncology Group trial (GOG 172). Proc Am Soc. Clin. Oncol A 803Google Scholar
  26. 26.
    Kirmani S, Braly P, McClay E et al. (1994) A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecol Oncol 54: 338–44CrossRefPubMedGoogle Scholar
  27. 27.
    Gadduci A, Carnino F, Chiara S et al. (2000) Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest. Gynecol Oncol 76: 157–62Google Scholar
  28. 28.
    Polyzos A, Tsavaris N, Kosmas C et al. (1999) A comparitive study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer. Oncology 56: 291–6CrossRefPubMedGoogle Scholar
  29. 29.
    Yen MS, Juang CM, Lai CR et al. (2001) Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. Int J Gynaecol Obstet 72: 55–60CrossRefPubMedGoogle Scholar
  30. 30.
    McGuire M, Hoskins W, Brady M et al. (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1–6CrossRefPubMedGoogle Scholar
  31. 31.
    Omura GA, Brady MF, Look KY et al. (2003) Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. J Clin Oncol. 21: 2843–8PubMedGoogle Scholar

Copyright information

© Springer-Verlag France 2006

Authors and Affiliations

  • L. Gladieff

There are no affiliations available

Personalised recommendations